Gene editing approach explores FLT3 genetic mutations in Acute Myeloid Leukemia

Natalia Rivera-Torres, Ph.D., and colleagues have made their work on “Modeling pediatric AML FLT3 mutations using CRISPR/Cas12a- mediated gene editing” available in the journal of Leukemia & Lymphoma. As the lead author, Dr. Rivera-Torres notes that clustered regularly interspaced palindromic repeats (CRISPR) with the associated (Cas) nuclease complexes have democratized genetic engineering through their precision and ease-of-use. Please feel free to get in touch with the lab to learn more about how they applied a variation of this technology, known as CRISPR-directed mutagenesis (CDM), to reconstruct genetic profiles within the FLT3 gene of AML patients. Their approach took advantage of the versatility of CDM and built expression vectors that, in combination with a specifically designed donor DNA fragment, recapitulate simple and complex mutations within the FLT3 gene.